** Gene therapy developer Regenxbio's RGNX.O shares rise 4.5% to $8.15
** Co reports interim early-stage data for its experimental gene therapy, RGX-202, for the treatment of Duchenne muscular dystrophy (DMD)
** DMD causes skeletal and heart muscle weakness that quickly worsens with time
** The interim data from two additional patients, including one aged 3 years, builds on the favorable safety and efficacy profile seen in ages 4 and older - RGNX
** Co says there were no serious adverse events
** Co plans to share further functional early-stage data in H1 2025
** Including session gains, RGNX has fallen 63% in the past 12 months
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。